Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this draft document, contact Michael Pacanowski (CDER) at 301-796-3919 or the Office of Communication, Outreach, and Development (CBER) at 800-835-4709 or 240-402-8010.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2017
Clinical Pharmacology
Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
Guidance for Industry

Additional copies are available from:

Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

and/or

Office of Communication, Outreach, and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010 Email: ocod@fda.hhs.gov

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2017
Clinical Pharmacology
# TABLE OF CONTENTS

I. INTRODUCTION AND BACKGROUND ................................................................. 1

II. DEVELOPMENT AND REGULATORY CONSIDERATIONS .......................... 2
   A. Identification of Patients for Inclusion in Clinical Trials ............................... 2
   B. Generalizability of Findings .......................................................................... 3
   C. Benefit and Risk Determination and Labeling ............................................... 4
   D. Refining the Target Population/Indication After Initial Approval ................. 4
I. INTRODUCTION AND BACKGROUND

Insights into the molecular basis of disease have led to the development of targeted therapies. Often, the pharmacological effect of a targeted therapy is related to a particular molecular alteration. Many clinically defined diseases are caused by a range of different molecular alterations, some of which may occur at low frequencies, that impact common proteins or pathways involved in the pathogenesis of diseases. In a population of patients with the same clinical disease, the heterogeneity in the molecular etiology may result in different responses to a particular targeted therapy. However, certain targeted therapies may be effective in multiple groups of patients who have different underlying molecular alterations. Therefore, FDA is providing guidance on the type and quantity of evidence that can demonstrate efficacy across molecular subsets within a disease, particularly when one or more molecular subsets occur at a low frequency.

The purpose of this guidance is to describe: (1) the FDA’s current recommendations on how to group patients with different molecular alterations for eligibility in clinical trials; and (2) general

---

1 This guidance has been prepared by the Office of Translational Sciences in the Center for Drug Evaluation and Research in cooperation with the Center for Biologics Evaluation and Research at the Food and Drug Administration.

2 For the purpose of this guidance, a targeted therapy is defined as a drug intended for populations that are subsets of clinically defined diseases and that are identified by using diagnostic testing. For the purposes of this guidance, all references to drugs include both human drugs and therapeutic biological products unless otherwise specified.

3 For the purpose of this guidance, molecular alteration refers to a broad array of molecular changes in DNA, RNA, or protein, including point mutations, gene fusions, mutational load, epigenetic changes, and over- or under-expression. Molecular subset refers to a subgroup of the clinically defined disease caused by a specific molecular alteration or group of molecular alterations that are observed in the clinical disease.
approaches to evaluating the benefits and risks of targeted therapies within a clinically defined
disease where some molecular alterations may occur at low frequencies.\(^4\)

In general, FDA’s guidance documents do not establish legally enforceable responsibilities.
Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only
as recommendations, unless specific regulatory or statutory requirements are cited. The use of
the word *should* in Agency guidances means that something is suggested or recommended, but
not required.

II. DEVELOPMENT AND REGULATORY CONSIDERATIONS

A. Identification of Patients for Inclusion in Clinical Trials

- The appropriateness of pursuing an indication in a molecular subset of a disease depends
on the strength of evidence supporting the hypothesis that patients with the molecular
alteration of interest will be more likely to respond to the targeted therapy owing to some
property of the drug (e.g., based on a putative mechanism of action or previous clinical
experience with the drug) than patients without the molecular alteration.

- If a sponsor is pursuing an enrichment strategy based on molecular criteria for the
purposes of clinical trial design and eligibility, the FDA will accept grouping patients
with different molecular alterations if it is reasonable to expect that the grouped patients
will have similar pharmacological responses based on a strong scientific rationale.\(^5\) The
rationale for grouping patients can be based on computational (e.g., in silico),
experimental (e.g., in vitro or animal experiments), or clinical evidence. Sponsors should
discuss any proposed grouping strategy with the FDA.

- Types of evidence that could support a grouping strategy are listed below in general order
of decreasing strength, although other sources of evidence may also be appropriate.
When more than one of these observations are present, the strength of the evidence
increases.

  - **Clinical studies**: Preliminary studies demonstrate patients with the proposed group
of specific molecular alterations exhibit similar responses to the investigational drug
based on a clinical efficacy endpoint or pharmacodynamic (PD) biomarker.

---

\(^4\) For the purpose of this guidance, *low-frequency* molecular alterations are those that occur at frequencies low
enough that enrolling a sufficient number of patients to conduct a clinical trial limited to the specific molecular
alteration of interest is not feasible or practical.

\(^5\) For further discussion on clinical trial enrichment strategies, refer to the draft guidance for industry *Enrichment
Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products*. When final, this
guidance will represent the FDA’s current thinking on this topic. For the most recent version of a guidance, check
the FDA Drugs guidance web page at
Nonclinical studies: Consistent drug effects are observed across a model system with the proposed group of molecular alterations in nonclinical studies.

In silico or mechanism-based evidence: The investigational drug is expected to have a consistent effect across patients with the proposed group of molecular alterations based on computational studies or mechanistic rationale (e.g., all protein truncating mutations or over-expression of the drug target in tumor tissue).

Evidence from other drugs in the same pharmacological class: Drugs with a mechanism of action similar to the drug under investigation show consistent effects across the proposed group of molecular alterations in a nonclinical model or clinical trials.

Phenotypic characterization of molecular alterations: The proposed group of molecular alterations shows consistent effects on relevant disease-related nonclinical or clinical phenotypes (e.g., mutations that result in increased activity of the drug target).

Sponsors should use analytically validated assays for the identification of molecular alterations used for enrollment of patients into clinical trials. The FDA recognizes that the clinical trial assay method may limit who is eligible for clinical trials. Ideally, clinical trial assays should be designed to detect all possible molecular alterations that comprise the group that is expected to respond (e.g., as detected through next-generation sequencing).

B. Generalizability of Findings

Targeted therapies may be effective in multiple molecular subsets that make up a clinical disease. However, the FDA anticipates that for certain subsets only a small number of patients (or even none despite eligibility criteria that are inclusive of such patients) will be enrolled into the trial. The low numbers or the absence of such patients would in most settings preclude meaningful empirical inferences about treatment benefits or risks in patients with those particular molecular alterations. However, when sponsors follow the principles for grouping patients set out in section II.A., Identification of Patients for Inclusion in Clinical Trials, extrapolation across multiple subsets may be possible despite the low frequency or absence of patients in some subsets.

Given the above considerations, if the clinical trials are successful and other conditions for approval are met, the FDA will, in most circumstances, approve the drug for all patients who meet the inclusion criteria for the trial based on the prespecified criteria, irrespective of the extent to which patients with various molecular alterations were represented in the clinical trial. Substantial evidence of effectiveness for the drug in the

---

6 For additional information, see the draft guidance for industry and FDA staff Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product. When final, this guidance will represent the FDA’s current thinking on this topic. For the most recent version of a guidance, check the FDA Drugs guidance web page at https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
indicated population would be based on the strength of evidence (see section II.A., Identification of Patients for Inclusion in Clinical Trials) demonstrating that patients in the molecular grouping defined by the inclusion criteria will respond similarly to the patients who participated in the study. As with all new drug approvals, the FDA will consider the totality of evidence in weighing the benefits and risks of the drug. If after trial enrollment the FDA or sponsor newly identifies a substantial scientific issue essential to determining the safety or effectiveness of the drug in some molecular subset included in the trial, the indicated patient population may be narrower than the clinical trial enrollment criteria.

C. Benefit and Risk Determination and Labeling

• Labeling will reflect the overall benefits and risks of the drug in the target population. When the drug is approved for all patients who meet the inclusion criteria for the registration trials as discussed in section II.B., Generalizability of Findings, the INDICATIONS AND USAGE statements should be sufficiently broad to include treatment of patients with low-frequency molecular alterations who would have been eligible for the trial irrespective of the extent to which they were represented in clinical trials. The studies informing the basis for grouping patients (e.g., cell or animal models, PD data) should be clearly specified (e.g., under CLINICAL PHARMACOLOGY or CLINICAL STUDIES).

• Evidence supporting the efficacy of the drug for each molecular subset should be transparently displayed (e.g., tabulation of the number of cases with specific molecular alterations that were enrolled in the clinical trial and the outcomes of the cases) under CLINICAL STUDIES.

• When accurate testing for molecular alterations (whether as a class or as specific alterations) is essential for the safe and effective use of the drug, an FDA-cleared or -approved assay should be commercially available at the time of drug approval to identify patients in the clinical setting. The FDA may grant exceptions when the drug is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists, and FDA determines that the benefits from the use of the drug outweigh the risks from the lack of an approved or cleared in vitro companion diagnostic device.  

D. Refining the Target Population/Indication After Initial Approval

• Incremental expansion of the population eligible for a drug may be part of a lifecycle strategy. The amount and nature of clinical efficacy data needed to expand a drug’s indication depends on the similarity of pharmacologic responses and the mechanistic rationale for the drug’s effect in the population for which efficacy was initially established and in the population to which the indication is being expanded. Similarly, if emerging data from studies (whether observational or randomized trials) indicates lack of

---

7 For additional information, see the guidance for industry and FDA staff *In Vitro Companion Diagnostic Devices.*
efficacy in certain molecular subgroups for which the drug was initially indicated, then, the FDA will consider narrowing the intended population.

- In some cases, generating data in the postmarket setting may be necessary to provide additional information regarding the risks and benefits of the drug in subsets of patients with limited or no enrollment in clinical trials. Real world evidence (e.g., from observational studies or registry data), traditional controlled trials, or data from other sources may be appropriate. As with all drug development programs, if the FDA approves the drug under the accelerated approval program\(^8\) or identifies safety concerns during the review process, the FDA may require postmarketing studies.

\(^8\) See the guidance for industry *Expedited Programs for Serious Conditions—Drugs and Biologics.*